The virus used in the experiments will be G47Δ, a third-generation recombinant Herpes simplex type I virus, and the target will be patients suffering from advanced glioblastoma. Clinical studies on patients suffering from advanced olfactory neuroblastoma and from hormone treatment-resistant recurrent prostate cancer are also underway.

University of Tokyo press release, Dec. 18, 2014